Showcases Stock ranks Forex

Momentum Stock Watch: uniQure N.V. (QURE)

-- Sunday, January 15, 2023, 10:51 --

Company Profile:

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Recent News:

On Dec. 20, 2022, the company announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 each in accordance with Nasdaq Listing Rule 5635(c)(4).

On Nov. 22, 2022, the company has received approval from the U.S. Food and Drug Administration (FDA) for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.

As of September 30, 2022, the Company held cash and cash equivalents of $440.3 million, compared to $556.3 million as of December 31, 2021. Collaboration revenue for the three months ended September 30, 2022, was $1.4 million, compared to collaboration revenue of $2.0 million for the same period in 2021.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects:

Price to Book Value – P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.


Price to Earnings – PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).


Discounted cash flow – DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.


Return on Assets – ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.


Return on Equity – ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.


Debt to Equity – evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.



QURE receives outperform rating in price to book value, discounted cash flow and debt to equity. Technical indicators signal the bullish signs, as there is a bullish crossover in the Stochastic oscillator, the MACD is trying to cross back up and the RSI(14) stands at 53 with positive bias. We rate uniQure N.V. (QURE) a STRONG BUY.

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator